vs
Biodexa Pharmaceuticals Plc（BDRX）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
Biodexa Pharmaceuticals Plc是一家处于临床阶段的生物制药企业，专注于开发癫痫、罕见神经退行性疾病等中枢神经系统疾病的创新疗法，主要面向欧美市场推进多款在研药物的临床试验，满足未被覆盖的患者治疗需求。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
BDRX
ZTS
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
净利润BDRXZTS
| Q4 25 | — | $603.0M | ||
| Q3 25 | — | $721.0M | ||
| Q2 25 | — | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | — | $682.0M | ||
| Q2 24 | — | $624.0M | ||
| Q1 24 | — | $599.0M |
毛利率BDRXZTS
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
营业利润率BDRXZTS
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | — | 34.1% |
净利率BDRXZTS
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | — | 28.6% | ||
| Q2 24 | — | 26.4% | ||
| Q1 24 | — | 27.4% |
每股收益（稀释后）BDRXZTS
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | — | $1.50 | ||
| Q2 24 | — | $1.37 | ||
| Q1 24 | — | $1.31 |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
